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Abstract 
Background: Osteoarthritis (OA) is a common arthritic disease and multifactorial whole‑joint disease. Interactions of 
chemokines and OA is inadequately documented.
Results: In vivo and in vitro studies were conducted to investigate monocyte chemoattractant protein 1 (MCP‑1) and 
receptor chemokine (C–C motif ) receptor 2 (CCR2) in chondrocyte degradation and cartilage degeneration. Chondro‑
cytes from 16 OA patients and 6 normal controls were involved in this study. After stimulation of MCP‑1, the expres‑
sion of MCP‑1 and CCR2 increased significantly (P < 0.001) and the expression of MMP‑13 also increased (P < 0.05). 
MCP‑1 stimulation also induced (or enhanced) the apoptosis of OA chondrocytes (P < 0.05). Additionally, the degra‑
dation of cartilage matrix markers (metalloproteinase 3 and 13, MMP3 and MMP13) in the culture medium of normal 
chondrocytes was also assessed. Furthermore, intra‑articular injection of MCP‑1 in mouse knees induced cartilage 
degradation and the CCR2 antagonist did not impede cartilage destroy in rats knees of monosodium iodoacetate 
(MIA) model.
Conclusions: The results of this study demonstrate that the MCP‑1‑CCR2 ligand‑receptor axis plays a special role in 
the initiation and progression of OA pathology. Patients with ambiguous etiology can gain some insight from the 
MCP‑1‑CCR2 ligand‑receptor axis.
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Background
OA is a common arthritic disease and multifactorial 
whole-joint disease. It has been recently redefined as a 
disease that affects the whole joint, including cellular 
changes, structural defects and dysfunction of all the 
joint compartments, e.g. cartilage, bone and synovium, 
the etiology of the disease is not completely defined [1–
3]. Despite its widespread occurrence in the aged popu-
lation, the pathogenesis of OA remains largely unknown.
The normal balance between synthesis and degra-
dation of the cartilage matrix is biased toward degra-
dation, and it has been shown that cytokines such as 
interleukin-1 (IL-1), chemokines like the C–C class 
of the beta chemokine family and tumor necrosis fac-
tor (TNF), as well as functional changes of the chon-
drocytes themselves, play major roles in the process of 
deterioration by inducing expression of proteinases, 
such as those of the MMP family. MCP-1 is a member 
of the C–C class of the beta chemokine family and one 
of the key factors involved in the initiation of inflamma-
tion. It triggers chemotaxis and transendothelial migra-
tion of monocytes to inflammatory lesions by interacting 
with the membrane CCR2 in monocytes [4]. MCP-1 
is secreted by fibroblasts, endothelial cells, vascular 
smooth muscle cells, monocytes, T cells, and other cell 
types that mediate or are involved in the influx of cells 
to and at sites of inflammation [5]. MCP-1 expression 
has been observed in a large number of tissues during 
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inflammation-dependent disease progression, including 
atherosclerosis [6], arthritis [7] and cancer [4].
As shown in early studies, OA is characterized by the 
degradation of cartilage, as the main (or unique) cell in 
cartilage; the chondrocyte plays an important role in car-
tilage degeneration and OA disease pathology [8–10]. We 
hypothesized that, despite the cytokines, the chemokines 
alone may also mediate certain independent interac-
tions with chondrocytes and play a role in the pathol-
ogy of OA. In this study, we investigated the interaction 
between MCP-1 and chondrocytes and the possible role 
of MCP-1-CCR2 ligand-receptor axis in cartilage degra-
dation and disease progression in osteoarthritis.
Results
The expression of MCP‑1‑CCR2 axis genes and cartilage 
matrix markers after stimulation of MCP‑1
Initially, we confirmed the presence and level of MCP-1 
and CCR2 mRNAs in cultured human articular chondro-
cytes [11, 12]. In a total of 11 paired samples from OA 
patients, with or without the stimulation of MCP-1, we 
observed statistically significant (P  <  0.001) increased 
expression of MCP-1 and CCR2 in stimulated chondro-
cytes (MCP-1 stim group) compared to the unstimulated 
controls (unaffected group) in each paired group (Fig. 1a, 
b). A comparative study of MCP-1 and CCR2 expression 
in a variety of chondrocytes and synovial fibroblast cells 
from OA, RA patients and healthy young patients was 
conducted. We observed that OA synovia fibroblasts had 
the highest expression of MCP-1; while CCR2 was mostly 
expressed in RA synovial fibroblasts (Fig. 1c, d).
We measured the level of chemokine protein MCP-1 
secreted by chondrocytes in response to MCP-1 itself in 
OA and wild-type (normal controls) chondrocytes. Three 
days after stimulation of MCP-1 in chondrocytes from 
OA patients, detectable amounts of MCP-1 protein were 
observed and the expression of MCP-1 was higher in 
stimulated samples than in unstimulated controls in each 
pair of groups (Fig. 1e). While both MMP3 and MMP13 
levels were elevated in response to MCP-1 stimulation in 
MCP-1 stimulated wild-type chondrocytes (N–M group) 
compared with unstimulated wild-type chondrocytes 
(N–N group), only MMP13 reached statistical signifi-
cance (P < 0.05) (Fig. 1f, g).
Chondrocyte apoptosis assessment and the expression 
of CCR2 in OA chondrocytes
To measure the rate of apoptosis by Annexin-V stain-
ing, we observed both stimulated and unstimulated OA 
had similar rates of apoptosis; however, the rate of sec-
ondary necrotic apoptotic chondrocytes was statistically 
significant higher in the stimulated compared with the 
unstimulated controls in each paired group (Fig.  2a, b). 
To quantify the expression of CCR2 protein, western blot 
analysis was performed. Results of western blot analysis 
revealed that the expression of CCR2 was lower in wild-
type (normal controls) OA controls; however, stimulation 
of OA chondrocytes with MCP-1 enhanced the expres-
sion of CCR2 in OA chondrocytes (Fig. 2c, d).
Micro‑CT analysis of subchondral bone changes in rats
According to micro CT observation, there were no sig-
nificant changes in bone surface density (BV/TV), bone 
volume density (BS/BV), trabecular thick (TREB-THI), 
trabecular bone number (TREB-N), and trabecular 
space (TREB-S) in the whole region of the two subgroups 
[CCR2 antagonist injection (MIA) and contralateral 
physiological saline] at 2 and 6 weeks after the last CCR2 
antagonist injection (Table 1). The CCR2 antagonist did 
not affect the parameters of the whole subchondral areas 
of femoral condyles and tibia, all the micro-CT analysis 
parameters can not reach a statistical difference between 
the pairs of each groups at each time point. The damage 
to the cartilage and subchondral bone of both experi-
mental and contralateral knees was obvious and serious 
(Fig. 3A, B).
Joint pathology scores in mice and rats
0, 4, 6, and 8 weeks following intra-articular injection of 
MCP-1 and 0.1 % BSA, semi-quantitative scoring of his-
tological assessments of both lateral knee joints was made 
according to the OARSI initiate [13]. We can obviously 
see that the MCP-1 induced more serious knee joint 
damage than the contralateral control knee in the Safra-
nin-O photomicrographs scoring results. 2 and 6 weeks 
after CCR2 antagonist injection, we examined the effect 
by H & E staining of rats’ knee joints (Fig.  4A, B). Car-
tilage degeneration score parameters described by the 
OARSI initiate [14] were acquired and counted. After the 
intra-articulate injection of MIA and CCR2 antagonist 
or physiological saline, the cartilage degeneration score 
of each knee of all slides reached the maximum grade of 
five (Fig. 4C). The variance between the experimental and 
contralateral knees were not statistically significant.
Discussion
Despite the widespread prevalence of OA, its etiology is 
still unknown. Currently, known OA risk factors are not 
fully and clear accordant with the clinical OA etiologies. 
There have been many previous studies focused on the 
roles of cytokines and chemokines in the pathological 
process of OA [15].
MCP-1 is one of the chemokines which is involved in 
osteoarthritis, the ligand is CCR2. MCP-1 is believed to 
play a key role in the inflammation process [16]. Whether 
OA is caused by inflammatory changes or simply because 
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the biomechanics of human joint abnormalities is con-
tentious at present [17]. However,the classification of OA 
as a kind of arthritis and having some inflammation in 
joints is without much argument. Whether systemic or 
localized inflammation in focal joints is strongly associ-
ated with the origination and severity of OA, especially 
in those patients with normal joint mechanism, without 
previous trauma in/near focal joints, and with the exclu-
sion of other risk factors, cannot be easily recognized. 
The role of MCP-1 in focal joints as risk factor of OA was 
unconfirmed. Our work focused on the role of MCP-1 as 
a key mediator of focal, not systemic, inflammation [18].
In our present study, we confirmed that MCP-1 oper-
ates in a positive feedback mechanism in wild-type (nor-
mal controls) and OA chondrocytes. Our experiments 
showed that increased MCP-1 promoted apoptosis while 
simultaneously inhibiting the proliferation of wild-type 
(normal controls) and OA cartilage cells under nor-
mal culture conditions. From our quantitative data, we 
determined that elevated MCP-1 levels promoted the 
pathogenesis of OA more so than other joint disorders, 
such as RA. Furthermore, we observed that an increase 
in MCP-1 levels in our culture system also resulted in an 
increase in its ligand, CCR2. Additionally, the stimula-
tion of MCP-1 expression in wild-type (normal controls) 
chondrocytes resulted in the increased expression of 
degeneration proteins, MMP3 and MMP13, suggesting 
that MCP-1 attracted macrophages and other inflamma-
tory cells to the joint and elicited an effect on cartilage 
cells at the same time. Through the results in our present 
study, we speculate that MCP-1 expedites the  damage 
of cartilage by enhancing the apoptosis of chondrocytes 
while inhibiting their proliferation. Furthermore, we 
believe that MCP-1 induced degenerative changes in 
wild-type (normal controls) cartilage cells under our cul-
ture conditions.
Similar to our cell culture experiments, we observed 
inflammation and cartilage damage in our in vivo study 
after intra articular injection (IA) of MCP-1 in the knee 
joints of mice. The joint pathology changes induced by 
Fig. 1 The expression of MCP‑1‑CCR2 axis genes and cartilage matrix markers after stimulation of MCP‑1. a, b In OA chondrocytes, after stimulation 
of MCP‑1 in culturing medium of the relative expression of MCP‑1 and CCR2 mRNA increased significantly compared with unaffected OA chondro‑
cytes; c, d the expression of Mcp‑1 in OA/CHON and OA/S.F were significantly higher than RA/SF and WT/CHON. The expression of Ccr2b in OA/
CHON were significantly lower than that in OA/S.F, RA/SF and WT/CHON. MCP‑1 Stim, MCP‑1 stimulated; RA/SF, RA synovial fibroblasts; OA/S.F, OA 
synovial fibroblast; OA/CHON, OA chondrocytes; WT/CHON, wild‑type (normal controls) chondrocytes; RA/CHON, RA chondrocytes; and e, f, g 
after stimulation of MCP‑1, the expression of MCP‑1 and MMP13 protein increased significantly than unstimulated normal OA chondrocytes. MMP3 
increased but there was not significantly higher than unstimulated normal chondrocytes. MCP‑1 Stim, MCP‑1 stimulated OA chondrocytes; N–N, 
unstimulated wild‑type (normal controls) chondrocytes; N–M, MCP‑1 stimulated wild‑type (normal controls) chondrocytes. *P < 0.05, **P < 0.01, 
***P < 0.001
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MCP-1 were significantly worse compared to the con-
tralateral control injected knees. We hypothesized that 
treatment of an MIA rat model with a CCR2 antagonist 
would improve the OA observed. However, we observed 
no significant improvement in the pathology scores in 
rats and the micro CT analysis in the whole knee joint 
was insignificant. While we confirmed the destructive 
effects of MIA injection into knee joints, we encountered 
setbacks with intra-articular injection. Aggressive sub-
chondral bone lesions form the basis for macroscopic 
evaluation [19, 20]. We would keep focus on developing 
structure-modifying treatments (disease-modifying OA 
drugs) by focusing on the CCR2 antagonist. Since there 
had been successful endeavors in system research of ani-
mal studies [21].
Modeling OA for research is rather complicated. While 
age has been confirmed to be a risk factor of OA; pres-
ently, we lack a suitable marker for diagnosis of OA dis-
ease [22]. Elevated levels of chemokines in serum in 
elderly individuals have been observed [23] and to quan-
tify the degree of MCP-1 and CCR2 increase in human 
tissue samples, we used samples from younger, unaffected 
patients as a control. It is possible that we have underes-
timated the degree of MCP-1 increase in elderly patients 
with OA since our control samples were obtained from 
tumor patients and MCP-1 is overexpressed in many 
tumors [4].
Conclusions
Taken together, the present study suggests that MCP-1 
induces the degradation of wild-type (normal controls) 
and OA chondrocytes. These effects were embodied in 
the inhibition of proliferation, induction of degeneration 
and apoptosis of the wild-type (normal controls) and OA 
chondrocytes. The damaging effects of MCP-1 on cartilage 
cells may be due to a positive feedback mechanism. Based 
on the results of our present study, we infer that MCP-1 
has a special role in the pathogenesis of OA and requires 
further investigation to delineate the MCP-1 pathway.
Methods
Patients
Articular cartilage and synovial membrane specimens 
were obtained from 18 OA (mean age 38  years, range 
18–65  years), 4 RA patients (mean age 64  years, range 
48–74  years) and 6 wild-type (normal controls, mean 
age 43  years, range 34–53  years) who were undergo-
ing total joint replacement at Peking University, People’s 
hospital, Beijing. All patients met the American College 
of Rheumatology criteria for OA (Altman R.1986), RA 
(2009 ACR/EULAR) [24]. Wild-type (normal controls) 
(normal) human cartilage was collected from the tibial 
plateau of 6 patients with practically no evidence of knee 
joint destruction who were undergoing joint replace-
ment because of femoral or pelvic malignant tumor. All 
Fig. 2 Chondrocyte apoptosis assessment and the expression of CCR2 in OA chondrocytes. a MCP‑1 stimulation of wild‑type (normal controls) 
chondrocytes resulted in an increased rate in secondary necrosis. Lower left quadrant represents viable cells, the lower right quadrant are chondro‑
cytes in an early apoptotic state, the upper right quadrant are chondrocytes in the late apoptotic state and the upper left quadrant is chondrocyte 
necrosis. N, unstimulated wild‑type (normal controls) chondrocytes; N–M, MCP‑1 stimulated wild‑type (normal controls) chondrocytes; b the vari‑
ance of early apoptotic state between the two subgroups was not significant and the variance in secondary necrotic rate and both was statistically 
significant; and c, d MCP‑1 stimulation in OA chondrocytes resulted in a significant increase in the expression of CCR2. Wild‑type (normal controls), 
unstimulated OA chondrocytes; MCP‑1, MCP‑1 stimulated OA chondrocytes. *P < 0.05
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samples were obtained with informed consent from the 
patients and the study protocol was approved by the eth-
ics committee of Peking University People’s Hospital.
Chondrocyte and synovial fibroblast isolation
Cartilage was minced and digested by rotating overnight 
at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco, Life Technologies, NY, USA) containing 1 mg/ml 
of bacterial collagenase II (Gibco). The cells released by 
enzymatic digestion were filtered through a sterile nylon 
strainer (Coring, NY, USA), washed, and centrifuged. 
The pellet was seeded into the six cm diameter Petri dish 
(Coring) at a density of 4  ×  105 cells and cultivated at 
37 °C in a humidified atmosphere of 5 % CO2. The culture 
medium used was DMEM containing 10  % heat-inac-
tivated fetal calf serum (Gibco), 100 units/ml penicillin 
(Gibco), and 100  mg/ml streptomycin (Gibco). Medium 
was replaced every week and cells were used between the 
second and third passages.
Tissues of Synovial membrane from OA and RA 
patients were minced and digested in DMEM contain-
ing 1 mg/ml of bacterial collagenase I (Gibco) for 3 h and 
then filtered and centrifuged the same as chondrocytes. 
The pellets was recognized as synovial fibroblasts, then 
seeded and cultivated at a density of 4  ×  105 cells, the 
culture medium employed the same as chondrocytes, and 
cells were used between the second and third passages.
Enzyme‑linked immunosorbent assay (ELISA)
After the medium was changed, cell monolayers were 
incubated with or without stimulation with recombi-
nant human MCP-1 (California Bioscience, Coachella, 
CA) at the indicated concentrations of 20  ng/ml for 
72  h. Supernatants were then collected and stored at 
−70  °C until used. MCP-1, collagen II and MMP3, 
MMP13 concentrations in the culture supernatants 
were evaluated with commercial ELISA kits, according 
to the instructions of the manufacturer. The ELISA kits 
Table 1 The parameter of micro-CT analysis of the rats knees (each pair of subgroup n = 6)
Scan parameters of the femur condyle, tibia and patella (X ± SEM)
BV/TV (%) BS/BV (mm−1) TREB‑THI (mm) TREB‑N (mm−1) TREB‑S (mm)
Femoral condyle
 2 week
  L 52.7 ± 6.8 17.825 ± 1.741 0.113 ± 0.011 4.651 ± 0.221 0.102 ± 0.019
  R 53.2 ± 4.9 17.512 ± 1.500 0.115 ± 0.010 4.635 ± 0.242 0.101 ± 0.014
 6 week
  L 71.5 ± 5.4 11.585 ± 1.220 0.174 ± 0.019 4.113 ± 0.151 0.069 ± 0.011
  R 74.5 ± 4.3 11.028 ± 0.967 0.183 ± 0.017 4.089 ± 0.170 0.062 ± 0.009
Tibial
 2 week
  L 53.1 ± 5.1 18.411 ± 1.733 0.109 ± 0.011 4.855 ± 0.289 0.097 ± 0.013
  R 53.6 ± 6.1 18.884 ± 2.003 0.107 ± 0.011 5.000 ± 0.112 0.093 ± 0.014
 6 week
  L 75.6 ± 4.8 11.108 ± 1.016 0.181 ± 0.017 4.180 ± 0.177 0.058 ± 0.011
  R 76.1 ± 6.0 11.274 ± 1.178 0.179 ± 0.018 4.262 ± 0.120 0.056 ± 0.013
Femoral condyle and tibial
 2 week
  L 52.6 ± 5.7 18.092 ± 1.568 9.506 ± 0.481
  R 53.4 ± 5.0 17.963 ± 1.365 9.634 ± 0.295
 6 week
  L 73.9 ± 5.4 11.233 ± 1.165 8.293 ± 0.322
  R 75.1 ± 4.8 11.117 ± 0.999 8.351 ± 0.272
Patella
 2 week
  L 78.0 ± 8.4 28.159 ± 41.708 0.159 ± 0.079 4.291 ± 0.552 0.047 ± 0.024
  R 80.6 ± 7.1 9.702 ± 2.143 0.214 ± 0.043 3.847 ± 0.481 0.049 ± 0.012
 6 week
  L 89.4 ± 4.3 6.944 ± 1.695 0.305 ± 0.083 3.074 ± 0.614 0.033 ± 0.008
  R 89.4 ± 2.2 24.565 ± 43.152 0.244 ± 0.113 10.852 ± 18.961 0.028 ± 0.013
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for this study were as follows: MCP-1(438807, LEGEND 
MAX, Biolegend, San Diego, CA 92121, USA), 7.8–
500 pg/ml; Collagen II (SEA572Hu, Cloud-Clone Corp. 
Huston, TX 77082, USA), 46.88-3000  pg/ml; MMP3 
(SCA101Hu, Cloud-Clone Corp. Huston, TX 77082, 
USA), 41.2–60,000 pg/ml; MMP13 (SCA099Hu, Cloud-
Clone Corp. Huston, TX 77082, USA). 54.9–160,000 pg/
ml.
Reverse transcriptase–polymerase chain reaction (RT‑PCR)
Total RNA was extracted from the chondrocytes using the 
single-step method (TRIzol Reagent, Invitrogen, Carls-
bad, CA, USA). First-strand complementary DNA (cDNA) 
was synthesized in a 10-μl reaction mixture by incubation 
at 37  °C for 5  min. The resulting cDNA (5  μl) was sub-
jected to PCR using SYBRGREEN (TOYOBO, OSAKA, 
JAPAN) and the specific primers for the chemokines, 
MCP-1, CCR2, collagen II and GAPDH were showed as 
follow: MCP-1: Sense ATAGCAGCCACCTTCATTCC, 
Antisense TTTCCCCAAGTCTCTGTATCT; CCR-2b: 
Sense GCGGAATCTTCTTCATCATCCTC, Antisense 




We harvested and washed the cells, and resuspended 
the cells in 1 × annexin-binding buffer, added 5 μl Alexa 
Fluor 488 annexin V and 1  μl 100  μg/ml PI working 
solution (V13241, MOLECULAR PROBES, invitrogen, 
Eugene, OR 97402, USA) to each 100 μl of cell suspension 
and incubated the cells at room temperature for 15 min. 
After incubation, 400 μl 1 × annexin-binding buffer was 
added and gently mixed, while keeping the samples on 
ice. The stained cells were analyzed by flow cytometry, 
measuring the fluorescence emission at 530 and 570 nm 
using 488 nm excitation.
Western blot
Protein samples were prepared by mixing sample with 
LDS Sample Buffer (Life Technologies, Carlsbad, CA, 
USA) and then boiled at 95  °C for 5 min. Proteins were 
separated on a NuPAGE 4–12 % Bis–Tris Gel (Life Tech-
nologies) and electro-transferred onto polyvinylidene dif-
luoride membranes. The membranes were blocked with 
5  % non-fat milk for 2  h at room temperature in Tris-
buffered saline containing 0.5  % Tween-20 (TBST). The 
membranes were then rinsed twice with TBST and incu-
bated with rabbit polyclonal to CCR2 (dilution of 1:2000, 
ab21667, Abcam, Shanghai, China) overnight at 4  °C, 
and then washed and incubated with corresponding goat 
anti-Rabbit antibody at room temperature for 1  h. Pro-
teins were visualized via chemiluminescence with Image-
Quant 350 (GE HEALTHCARE, Piscataway, NJ, USA).
Joint pathology in mice and rats
The procedures used in this study were approved by the 
ethics committee of Peking University People’s Hospital. 
Animals were provided with living conditions, food, and 
housing consistent with the approved animal care operat-
ing procedures.
Rats
Male Sprague–Dawley rats (175–200 g; Vital River Labo-
ratory, Beijing China) were allowed to acclimate to the 
facility for 7 days. Rats were anesthetized with 10 % Chlo-
ral hydrate (H20064279, Peking University People’s Hos-
pital) and given single intra-articular injection of 0.5 mg 
of MIA (Sigma, St. Louis, MO, USA) through the infrapa-
tellar ligament of the knee. MIA was dissolved in physi-
ologic saline and administered once in a volume of 25 µl 
using a 27-gauge, 0.5-inch needle in both knees. The right 
knee was the experimental, injected with 25 µl of CCR-2 
antagonist (Sigma), with the concentration of 50  ng/ml 
[25, 26] once a week, for 4  weeks and the contralateral 
(left) knee was treated as a control knee which received 
an injection of physiological saline. The first injection 
of CCR-2 antagonist or physiological saline was given 
3  days after the injection of MIA. The amount of MIA 
injected into the joint had been determined in a dose–
response study [27] and we finished the intra-articulate 
injection of MIA in an amount of 0.25 mg/joint.
Fig. 3 Micro‑CT analysis of subchondral bone changes in rats. A 
3D view of knee joint cartilage surface, severe cartilage damage 
existed in both MIA injected (a) and contralateral control (b) knees; 
B cartilage lost and subchondral bone osteosclerosis were severe in 
both femoral condyle and tibia in MIA injected (a) and contralateral 
(b) knees
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Micro‑CT analysis of subchondral bone changes in rats
Prior to histological sectioning, all rat knee joints were 
scanned using a micro-CT system (Inveon MM system, 
Siemens, Munich, Germany) with the following parame-
ters: 360 projections over 360° increment, 600 ms exposure 
time averaged per projection, voltage of 80 kV, current of 
500 μA, voxel size of 9.08 μm, and a scan time of approxi-
mately 20 min per knee. The reconstructed data sets were 
examined using three-dimensional data analysis software 
(Inveon Research Workplace, Siemens, Munich, Germany).
Histology
Tissue samples were prepared for light microscopy using 
standard procedures. Briefly, samples were fixed in 10 % 
phosphate-buffered formalin and subsequently decal-
cified in 5 % formic acid for 72 h. Frontal section joints 
were routinely processed to HE slides and examined 
under the light microscope. The joint degeneration was 
assessed with the OARSI cartilage degeneration score in 
histological assessments of the rats [14].
Mice
Male C57Bl/6 (Vital River Laboratory) mice aged 
10  weeks were used in all experiments. The right knee 
joints of the mice were injected once a week, for 3 weeks, 
intra-articularly through the patellar ligament, with a 
6-μl solution of MCP-1 (CB500038, California Biosci-
ence, Coachella, CA, USA) at a concentration of 25 ng/
ml. The dissolving agent was 0.1 % BSA, according to the 
manufacturer. At the same time, the left control knee 
joint was injected with 6  μl of 0.1  % BSA. Two mice, 
injected with MCP-1, were sacrificed by cervical disloca-
tion after an inhalation of ibuprofen at two time-points 
21 and 42 days, after intra-articular injection. Histologi-
cal assessments of knee joints in the mouse were adopted 
from the OARSI histopathology initiative [13].
Statistical analysis
Statistical analysis was performed with SPSS 21.0 (IBM 
SPSS, Chicago, IL, USA). Paired/unpaired t test was used 
to analyze significant difference between control and 
Fig. 4 Joint pathology scores in mice and rats. A Safranin‑O photomicrographs displaying a variety of OA severity and semi‑quantitative scores. 
First score represents femoral condyle, second score is tibia; a 0, 0; b 0.5, 0; c 0.5, 2; d 2, 4; e 1, 0.5; f 2, 4; g 1, 2; h 4, 6. Among these, a, c, e, g shows the 
contralateral knees and b, d, f, h shows the MCP‑1 intra‑articulate injection knees. B The OARSI semi‑quantitative scores of knees of each pairs of 
two subgroups at each time point; a scores of contralateral knees, despite some individuals with relatively high score (<2), most of the scores were 
low and stable; b scores of MCP‑1 intra‑articulate injection knees increased over time with some knees reaching the maximum score of 6. The rate 
of increase plateaued in later time‑points. C HE slides of rats’ knee joints, articular cartilage was almost completely lost in both experiment and 
contralateral knee at 2 week after CCR2 antagonist or physiological saline injection. a The lateral tibia plateau of contralateral knee; b medial tibia 
plateau of experimental knee following CCR2 antagonist intra‑articular injection. The cartilage degeneration score of Both A and B reached the 
highest grade of 5, at 2 weeks after CCR2 antagonist or physical saline injection
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experimental groups. All data, including Micro CT, was 
presented as the mean ± SEM. P < 0.05 was considered 
statistically significant. The results of ELISA were assayed 
by regression analysis, Curve Expert professional 2.2 
(Daniel G. Hyams) was used to draw the best standard 
curve. All the graphs were produced by Graphpad Prism 
5 (GraphPad Software, La Jolla, CA, USA).
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